These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

116 related items for PubMed ID: 8907135

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. Calcium sensitizers in chronic heart failure: inotropic interventions-reservation to preservation.
    Teramura S, Yamakado T.
    Cardiologia; 1998 Apr; 43(4):375-85. PubMed ID: 9659795
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Inodilator therapy for heart failure. Early, late, or not at all?
    Remme WJ.
    Circulation; 1993 May; 87(5 Suppl):IV97-107. PubMed ID: 8097971
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Hemodynamic effects of calcium-sensitizing agents.
    Vegh A, Papp JG, Udvary E, Kaszala K.
    J Cardiovasc Pharmacol; 1995 May; 26 Suppl 1():S20-31. PubMed ID: 8907128
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Effects of Ca2+ sensitizers on contraction, [Ca2+]i transient and myofilament Ca2+ sensitivity in diabetic rat myocardium: potential usefulness as inotropic agents.
    Ishitani T, Hattori Y, Sakuraya F, Onozuka H, Makino T, Matsuda N, Gando S, Kemmotsu O.
    J Pharmacol Exp Ther; 2001 Aug; 298(2):613-22. PubMed ID: 11454923
    [Abstract] [Full Text] [Related]

  • 10. Levosimendan: beyond its simple inotropic effect in heart failure.
    Antoniades C, Tousoulis D, Koumallos N, Marinou K, Stefanadis C.
    Pharmacol Ther; 2007 May; 114(2):184-97. PubMed ID: 17363065
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Calcium sensitising agents in heart failure.
    Mathew L, Katz SD.
    Drugs Aging; 1998 Mar; 12(3):191-204. PubMed ID: 9534020
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Classification of positive inotropic actions based on electrophysiologic characteristics: where should calcium sensitizers be placed?
    Varro A, Papp JG.
    J Cardiovasc Pharmacol; 1995 Mar; 26 Suppl 1():S32-44. PubMed ID: 8907129
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Direct myocardial effects of levosimendan in humans with left ventricular dysfunction: alteration of force-frequency and relaxation-frequency relationships.
    Givertz MM, Andreou C, Conrad CH, Colucci WS.
    Circulation; 2007 Mar 13; 115(10):1218-24. PubMed ID: 17339544
    [Abstract] [Full Text] [Related]

  • 20. New therapeutic targets for the development of positive inotropic agents.
    Tamargo J, Duarte J, Caballero R, Delpón E.
    Discov Med; 2011 Nov 13; 12(66):381-92. PubMed ID: 22127109
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 6.